Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02599649
Title Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

bone marrow cancer

Therapies

Nivolumab

Azacitidine

Lirilumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.